Navigation Links
Favrille Announces Workforce Reduction
Date:5/29/2008

SAN DIEGO, May 29 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL) today announced that it has provided a notice to 132 of its 144 employees, including six of its eight executive officers, that their employment with the Company will end on June 6, 2008. This workforce reduction follows the announcement earlier this week that the Company has discontinued development of its lead product, Specifid(TM), after it failed to show benefit in a Phase 3 registration trial.

The remaining employees will manage a plan to maximize the value of the Company's remaining cash, fixed assets and technology for the benefit of Favrille's creditors and shareholders.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research and clinical development programs. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to Favrille's ability to continue its operations, conserve cash or recognize value on our assets and additional risks discussed in Favrille's filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement. Favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statement
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkins Lymphoma
2. Favrille Reports First Quarter 2008 Financial Results
3. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
4. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
5. Favrille Announces $21.1 Million Registered Direct Offering
6. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
7. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
8. Favrille to Present at BIO InvestorForum
9. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
10. Favrille CEO to Present at Bear Stearns Healthcare Conference
11. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... The Remedy Group , the premier ... specialty pharmacy industry, will be exhibiting, presenting, and is ... Summit. The Summit will be held May 4-8, 2015 ... the largest annual gathering for the specialty pharmacy industry. ... providers, pharma/biotech manufacturers, and payers, to learn more about ...
(Date:5/5/2015)... RURO, Inc., a leading LIMS, RFID ... the latest major content upgrade to its bestselling, Commercial ... Upgrade is a significant advancement of FreezerPro® system ... experience, while also simplifying , New ... Download available immediately for free to “Gold” ...
(Date:5/5/2015)... May 5, 2015  Blueprint Medicines (NASDAQ: ... initial public offering of 9,367,708 shares of common ... per share, including shares of common stock issued ... their option to purchase additional shares. The gross ... Medicines were approximately $168.6 million, before underwriting discounts and ...
(Date:5/5/2015)... 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) ... the three months ended March 31, 2015 and provided ... in Canadian dollars. Effective July 17, ... May 31 to December 31. As a result of ... for the three months ended March 31, 2015, while ...
Breaking Biology Technology:The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 2RURO Releases version 7 of FreezerPro® software 2Blueprint Medicines Announces Closing of Initial Public Offering 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 8
... ... listed below, ST. LOUIS, June 13 ETHEX Corporation announced ... mg extended release tablets, and specific lots of morphine,sulfate 30 mg ... oversized tablets. Oversized tablets may contain as,much as two times the ...
... Conn., June 13 Alexion,Pharmaceuticals, Inc. (Nasdaq: ... President and Chief Financial Officer of Alexion,Pharmaceuticals, will ... Stock,Conference in Chicago at 9:10 a.m., local time ... An audio webcast of Mr. Sinha,s remarks will ...
... 13 Best Practices, LLC,s latest,benchmarking study explains ... CI operations while working within defined,guidelines., Particular ... is being,collected, and how CI groups work within ... collection that are in the best interests of,the ...
Cached Biology Technology:ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 2ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 3ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 4Pharmaceutical Competitive Intelligence Excellence: Optimizing Data Collection with Approved Guidelines 2
(Date:5/5/2015)... OXFORD, Conn. , May 5, 2015, NXT-ID, ... biometric authentication company focused on the growing mobile commerce market, ... the Company,s Chief Technology Officer, is presenting  at CARTES SECURE ... May 5-7, 2015. The three-day conference ... session David is speaking in is themed Global Fraud: ...
(Date:4/27/2015)... , April 27, 2015  For more than four ... show has been the premier worldwide event for the ... is a must-attend event for any local, national, or ... the emerging commercial markets and current applications of unmanned ... of this projected $48 billion industry, and how it ...
(Date:4/27/2015)... , Apr. 27, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... to pre-order customers the first week of May, 2015 ... month of May. Gino Pereira ... milestone for the company as Wocket® enters the consumer ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3
... Rising crime rates and terrorism around the globe ... reliable border control systems. These security concerns and ... immigration at all entry points, whether air, land ... vertical across Asia-Pacific. New analysis from ...
... ROCHESTER, N.Y., Oct. 24, 2012 VirtualScopics, Inc. (NASDAQ: ... announced that before the market opens on Friday, November ... financial results. VirtualScopics, President and Chief Executive Officer, Jeff ... will host a conference call that morning at 11:00 ...
... WOBURN, Mass., Oct. 24, 2012  Covaris Inc. announced ... Technologies Corporation enabling Life Technologies to offer the ... Torrent Next-Generation Sequencing platforms. Compact, cost ... the ideal fragmenting system for PGM™ and Proton™ ...
Cached Biology News:Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 2Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 3Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 4VirtualScopics Schedules Third Quarter 2012 Earnings Announcement 2
HOXC11 Antibody...
PPOX Immunogen: PPOX (AAH02357, 378 a.a. ~ 478 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Mouse monoclonal [SIT-01] to SIT ( Abpromise for all tested applications). entrezGeneID: 27240 SwissProtID: Q9Y3P8...
Biology Products: